Skip to main content

Articles

Page 5 of 34

  1. The prognosis for diffuse gliomas is very poor and the mechanism underlying their malignant progression remains unclear. Here, we aimed to elucidate the role and mechanism of the RNA N6,2′-O-dimethyladenosine (m6

    Authors: Rui-Chao Chai, Yu-Zhou Chang, Xin Chang, Bo Pang, Song Yuan An, Ke-Nan Zhang, Yuan-Hao Chang, Tao Jiang and Yong-Zhi Wang
    Citation: Journal of Hematology & Oncology 2021 14:109
    Content type: Research Published on:

  3. Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we a...

    Authors: Marius Bill, Krzysztof Mrózek, Brian Giacopelli, Jessica Kohlschmidt, Deedra Nicolet, Dimitrios Papaioannou, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Clara D. Bloomfield and Christopher C. Oakes
    Citation: Journal of Hematology & Oncology 2021 14:107
    Content type: Letter to the Editor Published on:

  4. CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously de...

    Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han
    Citation: Journal of Hematology & Oncology 2021 14:106
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:150

  5. FLT3 mutations are the most frequently identified genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Multiple FLT3 inhibitors are in various stages of clinical evaluati...

    Authors: Peihong Wang, Xinhua Xiao, Yuyin Zhang, Baoyuan Zhang, Donghe Li, Mingzhu Liu, Xi Xie, Chenxuan Liu, Ping Liu and Ruibao Ren
    Citation: Journal of Hematology & Oncology 2021 14:105
    Content type: Letter to the Editor Published on:

  7. The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofi...

    Authors: Graeme Greenfield, Mary Frances McMullin and Ken Mills
    Citation: Journal of Hematology & Oncology 2021 14:103
    Content type: Review Published on:

  8. T-cell receptor (TCR)-based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process th...

    Authors: Apostolia-Maria Tsimberidou, Karlyle Van Morris, Henry Hiep Vo, Stephen Eck, Yu-Feng Lin, Jorge Mauricio Rivas and Borje S. Andersson
    Citation: Journal of Hematology & Oncology 2021 14:102
    Content type: Review Published on:

  9. KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes...

    Authors: Shaneice Mitchell, Pu Zhang, Matthew Cannon, Larry Beaver, Amy Lehman, Bonnie Harrington, Deepa Sampath, John C. Byrd and Rosa Lapalombella
    Citation: Journal of Hematology & Oncology 2021 14:101
    Content type: Letter to the Editor Published on:

  10. Although checkpoint-based immunotherapy has shown exciting results in the treatment of tumors, around 70% of patients have experienced unresponsiveness. PVRIG is a recently identified immune checkpoint recepto...

    Authors: Yangyang Li, Yu Zhang, Guoshuai Cao, Xiaodong Zheng, Cheng Sun, Haiming Wei, Zhigang Tian, Weihua Xiao, Rui Sun and Haoyu Sun
    Citation: Journal of Hematology & Oncology 2021 14:100
    Content type: Research Published on:

  11. The human ζ-globin gene (HBZ) is transcribed in primitive erythroid cells only during the embryonic stages of development. Reactivation of this embryonic globin synthesis would likely alleviate symptoms both in α...

    Authors: Huiqiao Chen, Zixuan Wang, Shanhe Yu, Xiao Han, Yun Deng, Fuhui Wang, Yi Chen, Xiaohui Liu, Jun Zhou, Jun Zhu and Hao Yuan
    Citation: Journal of Hematology & Oncology 2021 14:99
    Content type: Letter to the Editor Published on:

  12. Tumors are not only aggregates of malignant cells but also well-organized complex ecosystems. The immunological components within tumors, termed the tumor immune microenvironment (TIME), have long been shown t...

    Authors: Tong Fu, Lei-Jie Dai, Song-Yang Wu, Yi Xiao, Ding Ma, Yi-Zhou Jiang and Zhi-Ming Shao
    Citation: Journal of Hematology & Oncology 2021 14:98
    Content type: Review Published on:

  13. T cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype that comprises 10–15% of childhood and 20–25% of adult ALL cases. Over 70% of T-ALL patients harbor activating mutations in the NOTCH1 signali...

    Authors: Inge Govaerts, Cristina Prieto, Charlien Vandersmissen, Olga Gielen, Kris Jacobs, Sarah Provost, David Nittner, Johan Maertens, Nancy Boeckx, Kim De Keersmaecker, Heidi Segers and Jan Cools
    Citation: Journal of Hematology & Oncology 2021 14:97
    Content type: Research Published on:

  14. Older patients (≥ 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemi...

    Authors: Alice S. Mims, Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrόzek, Eytan Stein, Bhavana Bhatnagar, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd…
    Citation: Journal of Hematology & Oncology 2021 14:96
    Content type: Research Published on:

  15. Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intraveno...

    Authors: Jian Li, Yanhong Deng, Weijie Zhang, Ai-Ping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu and Lin Shen
    Citation: Journal of Hematology & Oncology 2021 14:95
    Content type: Rapid communication Published on:

  16. The natural course of untreated chronic myeloid leukemia (CML) is progression to an aggressive blast phase. Even in the current era of BCR-ABL1 tyrosine kinase inhibitors (TKIs), the outcomes of blast phase CM...

    Authors: Kapil Saxena, Elias Jabbour, Ghayas Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti, Naval Daver, Tapan Kadia, Courtney D. DiNardo, Marina Konopleva, Jorge E. Cortes, Musa Yilmaz, Kelly Chien, Sherry Pierce, Hagop Kantarjian and Nicholas J. Short
    Citation: Journal of Hematology & Oncology 2021 14:94
    Content type: Research Published on:

  17. Small non-coding RNAs (ncRNAs) are vital regulators of biological activities, and aberrant levels of small ncRNAs are commonly found in precancerous lesions and cancer. PIWI-interacting RNAs (piRNAs) are a nov...

    Authors: Silu Chen, Shuai Ben, Junyi Xin, Shuwei Li, Rui Zheng, Hao Wang, Lulu Fan, Mulong Du, Zhengdong Zhang and Meilin Wang
    Citation: Journal of Hematology & Oncology 2021 14:93
    Content type: Review Published on:

  18. Hypoxia inducible factor-1α (HIF-1α) up-regulates the expression of programmed death ligand-1 (PD-L1) in some extracranial malignancies. However, whether it could increase PD-L1 expression in intracranial tumo...

    Authors: Xing-chen Ding, Liang-liang Wang, Xue-dong Zhang, Jun-long Xu, Pei-feng Li, Hua Liang, Xian-bin Zhang, Li Xie, Zi-han Zhou, Jia Yang, Ralph R. Weichselbaum, Jin-ming Yu and Man Hu
    Citation: Journal of Hematology & Oncology 2021 14:92
    Content type: Letter to the Editor Published on:

  19. Single-cell sequencing, including genomics, transcriptomics, epigenomics, proteomics and metabolomics sequencing, is a powerful tool to decipher the cellular and molecular landscape at a single-cell resolution...

    Authors: Yalan Lei, Rong Tang, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu and Si Shi
    Citation: Journal of Hematology & Oncology 2021 14:91
    Content type: Review Published on:

  20. The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years....

    Authors: Mengying Ke, Liqing Kang, Ling Wang, Shu Yang, Yajun Wang, Haiyan Liu, Chunyan Gu, Hongming Huang and Ye Yang
    Citation: Journal of Hematology & Oncology 2021 14:90
    Content type: Letter to the Editor Published on:

  21. Accurate appraisal of burden of adolescents and young adults (AYAs) cancers is crucial to informing resource allocation and policy making. We report on the latest estimates of burden of AYA cancers in 204 cou...

    Authors: Yi Feng Wen, Meng Xuan Chen, Guosheng Yin, Ruitao Lin, Yu Jie Zhong, Qian Qian Dong and Hai Ming Wong
    Citation: Journal of Hematology & Oncology 2021 14:89
    Content type: Research Published on:

  23. Cases of thrombotic thrombocytopenia induced by coronavirus disease 2019 (COVID-19) vaccines have been reported recently. Herein, we describe the first case of another critical disorder, hemophagocytic lymphoh...

    Authors: Liang V. Tang and Yu Hu
    Citation: Journal of Hematology & Oncology 2021 14:87
    Content type: Letter to the Editor Published on:

  24. Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our ...

    Authors: Evangelos Terpos, Flora Zagouri, Michalis Liontos, Aimilia D. Sklirou, Konstantinos Koutsoukos, Christos Markellos, Alexandros Briasoulis, Eleni-Dimitra Papanagnou, Ioannis P. Trougakos and Meletios-Athanasios Dimopoulos
    Citation: Journal of Hematology & Oncology 2021 14:86
    Content type: Letter to the Editor Published on:

  26. There is no information on the impact of donor type in allogeneic hematopoietic stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis with post-transplant cyclophosphamide (PTC...

    Authors: Jaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, Boris Afanasyev, Moiseev Ivan Sergeevich, Emanuele Angelucci, Nicolaus Kröger, Yener Koc, Fabio Ciceri, J. L. Diez-Martin, Mutlu Arat, Simona Sica, Montserrat Rovira, Mahmoud Aljurf, Johanna Tischer, Bipin Savani…
    Citation: Journal of Hematology & Oncology 2021 14:84
    Content type: Research Published on:

  27. Challenges remain on the selection of patients who potentially respond to a class of drugs that target epigenetics for cancer treatment. This study aims to investigate TET2/DNMT3A mutations and antitumor activity...

    Authors: Sherry X. Yang, Melinda Hollingshead, Larry Rubinstein, Dat Nguyen, Angelo B. A. Larenjeira, Robert J. Kinders, Michael Difilippantonio and James H. Doroshow
    Citation: Journal of Hematology & Oncology 2021 14:83
    Content type: Research Published on:

  28. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for acute myeloid leukemia (AML). However, most patients experience relapse after allo-HSCT, with a poor progn...

    Authors: Qingya Cui, Chongsheng Qian, Nan Xu, Liqing Kang, Haiping Dai, Wei Cui, Baoquan Song, Jia Yin, Zheng Li, Xiaming Zhu, Changju Qu, Tianhui Liu, Wenhong Shen, Mingqing Zhu, Lei Yu, Depei Wu…
    Citation: Journal of Hematology & Oncology 2021 14:82
    Content type: Letter to the Editor Published on:

  29. Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies...

    Authors: Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic, Aldo Morrone…
    Citation: Journal of Hematology & Oncology 2021 14:81
    Content type: Research Published on:

  30. Precise methods for postoperative risk stratification to guide the administration of adjuvant chemotherapy (ACT) in localized colorectal cancer (CRC) are still lacking. Here, we conducted a prospective, observ...

    Authors: Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai…
    Citation: Journal of Hematology & Oncology 2021 14:80
    Content type: Research Published on:

  31. Long known as digestive organelles, lysosomes have now emerged as multifaceted centers responsible for degradation, nutrient sensing, and immunity. Growing evidence also implicates role of lysosome-related mec...

    Authors: Ziqi Zhang, Pengfei Yue, Tianqi Lu, Yang Wang, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2021 14:79
    Content type: Review Published on:

  32. Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells escape immune surveillance by promoting immunosuppression. Immunotherapy targeting inhibitory molecules like anti...

    Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Rami Manochakian, Yujie Zhao and Yanyan Lou
    Citation: Journal of Hematology & Oncology 2021 14:78
    Content type: Review Published on:

  34. Allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) and cord blood transplantation (CBT) are valid alternatives for patients without a fully human leukocyte antig...

    Authors: Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Hélène Labussière-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jürgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani…
    Citation: Journal of Hematology & Oncology 2021 14:76
    Content type: Research Published on:

  36. IDH1 and IDH2 mutations (IDH1/2Mut) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent developme...

    Authors: Mathieu Simonin, Aline Schmidt, Christophe Bontoux, Marie-Émilie Dourthe, Etienne Lengliné, Guillaume P. Andrieu, Ludovic Lhermitte, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Françoise Huguet, Isabelle Arnoux, Stéphane Ducassou, Elizabeth Macintyre, Virginie Gandemer, Hervé Dombret…
    Citation: Journal of Hematology & Oncology 2021 14:74
    Content type: Rapid communication Published on:

  37. Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adopt...

    Authors: Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos and Wilfred T. V. Germeraad
    Citation: Journal of Hematology & Oncology 2021 14:73
    Content type: Review Published on:

  38. Evidence suggests that platelets may directly interact with SARS-CoV-2, raising the concern whether ACE2 receptor plays a role in this interaction. The current study showed that SARS-CoV-2 interacts with both ...

    Authors: Shu Shen, Jingyuan Zhang, Yaohui Fang, Sihong Lu, Jun Wu, Xin Zheng and Fei Deng
    Citation: Journal of Hematology & Oncology 2021 14:72
    Content type: Letter to the Editor Published on:

  39. CD8+ T cell-mediated adaptive cellular immunity and natural killer (NK) cell-mediated innate immunity both play important roles in tumour immunity. This study aimed to develop therapeutic tumour vaccines based on...

    Authors: Zhaojin Yu, Wensi Liu, Ying He, Mingli Sun, Jiankun Yu, Xue Jiao, Qiang Han, Haichao Tang, Bing Zhang, Yunkai Xian, Jing Qi, Jing Gong, Wang Xin, Gang Shi, Fengping Shan, Rui Zhang…
    Citation: Journal of Hematology & Oncology 2021 14:71
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:158

  40. BCL‐2 inhibition through venetoclax (VEN) targets acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield 60–70% clinical response rates, the vast majori...

    Authors: Ralf Buettner, Le Xuan Truong Nguyen, Corey Morales, Min-Hsuan Chen, Xiwei Wu, Lisa S. Chen, Dinh Hoa Hoang, Servando Hernandez Vargas, Vinod Pullarkat, Varsha Gandhi, Guido Marcucci and Steven T. Rosen
    Citation: Journal of Hematology & Oncology 2021 14:70
    Content type: Research Published on:

  43. Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor t...

    Authors: Haolan Wang, Ming Guo, Hudie Wei and Yongheng Chen
    Citation: Journal of Hematology & Oncology 2021 14:67
    Content type: Review Published on:

  44. Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, ...

    Authors: Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng and Delong Liu
    Citation: Journal of Hematology & Oncology 2021 14:66
    Content type: Review Published on:

  45. Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated r...

    Authors: Julien Edeline, Roch Houot, Aurélien Marabelle and Marion Alcantara
    Citation: Journal of Hematology & Oncology 2021 14:65
    Content type: Review Published on:

  46. The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment rec...

    Authors: Anouk H. Eijkelboom, Linda de Munck, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, Luc J. A. Strobbe, Monique E. M. M. Bos, Marjanka K. Schmidt, Cristina Guerrero Paez, Marjolein L. Smidt, Maud Bessems, Janneke Verloop, Sabine Linn, Marc B. I. Lobbes, Aafke H. Honkoop, Desirée H. J. G. van den Bongard, Pieter J. Westenend…
    Citation: Journal of Hematology & Oncology 2021 14:64
    Content type: Research Published on:

  47. Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavaila...

    Authors: Johannes P. W. Heidbuechel and Christine E. Engeland
    Citation: Journal of Hematology & Oncology 2021 14:63
    Content type: Review Published on:

  49. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Yahui Ding, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen and Quan Zhang
    Citation: Journal of Hematology & Oncology 2021 14:61
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2016 9:93

  50. Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients...

    Authors: Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin…
    Citation: Journal of Hematology & Oncology 2021 14:59
    Content type: Letter to the Editor Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us